Business Wire

ALCON

15.12.2021 17:27:08 CET | Business Wire | Press release

Share
Alcon Continues Its Successful Rollout of PRECISION1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, continues its successful rollout of PRECISION1TM . The spherical lens is now available in key markets throughout Latin America and Asia, and PRECISION1 for Astigmatism is available in markets throughout Europe. PRECISION1 for Astigmatism and PRECISION1 sphere are also available throughout North America.

PRECISION1 contact lenses are designed to address the common reasons why 20% of new wearers drop out in the first three weeks: poor vision, poor comfort and handling issues.3 The lenses provide precise vision, long-lasting comfort and ease of handling to allow new wearers,1 especially those with long busy days, an exceptional lens-wearing experience.

Inspired from the water gradient lens material in DAILIES TOTAL1® , PRECISION1 is the first-and-only contact lens with Alcon’s proprietary SMARTSURFACE® Technology. This features a permanent, micro-thin, high-performance layer of moisture at the lens surface that helps support a stable tear film.4

A stable tear film is vital to visual performance and comfort, especially for contact lens wearers.5

“Reinforcing our mission to help people see brilliantly, we are proud of the PRECISION1 contact lens launch, designed for people with an on-the-go lifestyle, in many markets across the globe,” said Antoine Delgrange, Alcon Vice President for Vision Care International Marketing. “We understand the consumer journey can be challenging; so, as an added benefit, we are offering the opportunity for our customers to provide their new lens wearers with an exclusive activation program to make their introduction to contact lenses easy and enjoyable. The program includes resources to increase consumer confidence with their new lenses.”

“I think of PRECISION1 as the contact lens of the future. It’s so comfortable to wear and easy to fit that the wearing experience amazes my patients,” said Dr. Teodoro Tarud, optician and owner of Centro Óptico de la Costa, Columbia.*

The launch of PRECISION1 for Astigmatism provides a significant opportunity to attract new contact lens wearers. Studies show that 41% of patients have astigmatism that needs correction,6 but only 10% wear toric contact lenses.7 "Our patients love the comfort of PRECISION1! This is the best launch I have ever seen. We can fit more patient types now that toric and minus lenses are available," said Fiona Kavanagh, owner and optician at Jennings Opticians, Ireland.**

“We are committed to providing eye care professionals (ECPs) with a comprehensive portfolio of lens-wearing options based on the specific needs of their patients,” said Cheryl Donnelly, International Head of Professional Affairs at Alcon. “Now, with PRECISION1 and PRECISION1 for Astigmatism, ECPs and optical retailers can offer more lens wearers a next-generation contact lens with exceptional all-day performance.”

For more information, visit PRECISION1® One-Day Contact Lenses | PRECISION1® (myalcon.com)

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com .

* Teodoro Tarud is a paid Alcon consultant.

** Fiona Kavanagh is a paid Alcon consultant.

References

  1. Grant T, Tang A. A Survey of contact lens wearers and eye care professionals on satisfaction with a new smartsurface silicone hydrogel daily disposable contact lens. Clin Optom 2020;12:9–15.
  2. In a clinical study, wherein subjects were fitted with PRECISION1 for Astigmatism contact lenses (N=78 eyes); Alcon data on file, 2020.
  3. Sulley A, Young G, Hunt C, et al. Retention rates in new contact lens wearers. Eye & Contact Lens. 2018;44:S273-S282.
  4. In vitro analysis of verofilcon A contact lenses for surface properties; Alcon data on file 2019.
  5. Craig JP, Willcox MDP, Argueso P, et al. The TFOS international workshop on contact lens discomfort: Report of the contact lens interactions with tear film subcommittee. Invest Ophthalmol Vis Sci. 2013; 54:TFOS123-TFOS156.
  6. Luensmann D, Schaeffer J, Rumney N, et al. Spectacle prescriptions review to determine prevalence of ametropia and coverage of frequent replacement soft toric contact lenses. Contact Lens and Anterior Eye ; 2018; 41 (5); 412-420.
  7. Multi-Sponsor Surveys 2014 Gallup target market report.

Connect with us on

Facebook
LinkedIn

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release

CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and

Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release

Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr

SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release

Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,

SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release

Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi

Interactive Brokers Offers Eligible Clients Access to the Anthropic, PBC Initial Public Offering13.11.2026 11:00:00 CET | Press release

ADVERTISEMENT This advertisement constitutes an advertisement within the meaning of the Prospectus Regulation and marketing communication within the meaning of MiFID II and is prepared by and in the sole responsibility of Interactive Brokers Ireland Limited, North Dock One, 91/92 North Wall Quay, Dublin 1, D01 H7V7, Ireland, a firm authorized and regulated by the Central Bank of Ireland. Eligible clients of Interactive Brokers Ireland Limited can participate in the offering. Interactive Brokers Ireland Limited, part of Interactive Brokers Group (Nasdaq: IBKR), an automated global broker, today announced that eligible clients can participate in the initial public offering (the “Offering”) of Anthropic, PBC (the “Company”). Through the IBKR platform, eligible clients resident and located in Denmark, Finland, France, Germany, Ireland, the Netherlands, Norway, Spain, and Sweden can review the Offering and submit an application during the offer period, which is open for all eligible clients

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye